<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Method for treating cancer using oral arsenic trioxide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inventor(s)</strong></td>
<td>Kwong, YL</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>US Published patent application US 2008089949. Washington, DC: US Patent and Trademark Office (USPTO), 2008</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2008</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/176956">http://hdl.handle.net/10722/176956</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
METHOD FOR TREATING CANCER USING ORAL ARSENIC TRIOXIDE

Inventor: Yok-Lam Kwong, Hong Kong (HK)

Correspondence Address:
COOPER & DUNHAM, LLP
1185 AVENUE OF THE AMERICAS
NEW YORK, NY 10036

Appl. No.: 11/549,347
Filed: Oct. 13, 2006

ABSTRACT

The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation, involving administering effective amount of arsenic trioxide to an affected patient.
Figure 1A
Figure 1B
Figure 1C
Figure 2A
Figure 2B
Figure 3A
Figure 3B
Granta-519

Cyclin D1

GAPDH

0 0.5 1 2 4 8

As$_2$O$_3$ (μM)

Figure 4A
Figure 4B
Figure 5B
Figure 5C
Figure 6A
Figure 6B
Figure 7B
As$_2$O$_3$

GSK3$\beta$

IKK$\alpha/\beta$

CyclinD1

P

P

CyclinD1

P

Ub

20S/26S

degradation

Cell Cycle Arrest

Apoptosis

Figure 8
Before $\text{As}_2\text{O}_3$  

After $\text{As}_2\text{O}_3$

Figure 9A
Figure 9B
Before $\text{As}_2\text{O}_3$  \hspace{1cm} After $\text{As}_2\text{O}_3$

Figure 9C
METHOD FOR TREATING CANCER USING ORAL ARSENIC TRIOXIDE

FIELD OF THE INVENTION

[0001] This invention relates to methods of treating cancer by affecting expression, translation, and biological activity of cyclin D1 using arsenic trioxide.

REFERENCES

[0002] Several publications are referenced herein by Arabic numerals with parenthesis. Full citations for these references may be found at the end of the specification immediately preceding the claims. These references are incorporated herein by reference.

BACKGROUND OF THE INVENTION

[0003] Cyclin D1 is a D-type cyclin critically involved in the control of cell cycle. It assembles with its catalytic partners cyclin-dependent kinase 4 (CDK4) and CDK6 to form an active holoenzyme complex, which controls G1 progression and G1/S transition.1 The active holoenzyme complex phosphorylates the retinoblastoma protein RB. Phosphorylated RB releases the E2F family of transcription factors from inhibition, enabling E2Fs to coordinately regulate genes necessary for DNA replication and hence progression into S phase.2 Over-expression of cyclin D1 is demonstrable in many cancers, including cancers of the digestive tract, cancers of the female genital tract, and malignant lymphomas.

[0004] Owing to its important influence on the cell cycle, cyclin D1 expression is carefully regulated. Cyclin D1 gene mRNA and transcription appears to be constant through the cell cycle.3 However, a decline in cyclin D1 level occurs during S phase, which has been attributed to its increased proteasomal degradation.4 Cyclin D1 phosphorylation at a threonine residue at 286 (Thr-286) positively regulates its proteasomal degradation.5 Thr-286 phosphorylation is mediated by glycogen synthase kinase-3β (GSK-3β).6 In addition to targeting cyclin D1 to proteasomes, GSK-3β-induced Thr-286 phosphorylation also promotes cyclin D1 nuclear export, by increasing the binding of cyclin D1 to a nuclear export CRM1.7 Recently, it has been shown that the IkappaB kinase (IKK) alpha, IKKz, associates with and phosphorylates cyclin D1 also at Thr-286, thereby participating in the subcellular localization and turnover of cyclin D1.8

[0005] Mantle cell lymphoma (MCL) is a well-defined subtype of B cell lymphoma in the World Health Organization classification,9 and accounts for approximately 3-10% of all non-Hodgkin lymphomas.10 The chromosomal aberration t(11;14)(q13;q32) can be found in practically all cases of MCL.11 The translocation results in juxtaposition of the immunoglobulin heavy chain joining region on chromosome 14 to the cyclin D1 gene on chromosome 11.12 The molecular consequence of the translocation is to place cyclin D1 under the control of the immunoglobulin heavy chain gene enhancer,12 leading to over-expression of the cyclin D1 protein. Therefore, MCL is an important prototype of cancer formation due to over-expression of cyclin D1. It is a very useful model in the investigation of the contribution of cyclin D1 to cancer formation. Furthermore, it provides a pertinent model for the study of therapeutic agents in the treatment of cancers over-expression cyclin D1.

[0006] Although MCL accounts for approximately 3-8% of B-cell lymphomas, it is difficult to manage.13 Initial treatment with rituximab plus combination chemotherapy or purine analogues results in complete remission (CR) rates varying from 34-87%.14-6 However, relapses occur in most patients with prolonged follow up. Treatment options for relapsed patients are limited. Several novel approaches have been adopted, including the use of the proteasome inhibitor bortezomib,17,18 thalidomide19 and the mammalian target of rapamycin (mTOR) inhibitor temsirolimus.20 The overall response (OR) rates of these agents varied from 38-81%, but the CR rate was only 3-51%. Therefore, there is an urgent need to define novel treatment strategies for MCL.

[0007] Arsenic trioxide (As2O3) is a standard treatment for acute promyelocytic leukemia (APL).21 Additionally, it has shown clinical activity in other hematologic malignancies, notably lymphomas.22 The inventors have invented an oral arsenic trioxide preparation for the treatment of patients with blood cancers.23 Furthermore, the inventors have shown that oral As2O3 is highly efficacious for relapsed acute promyelocytic leukemia.24 Moreover, the inventors have shown that oral As2O3 causes a smaller prolongation of QT intervals, and therefore may provide a much safer drug for treating leukemia.25

[0008] Since cyclin D1 plays a pivotal role in the pathogenesis of MCL, the inventors tested the hypothesis that As2O3 might target cyclin D1 in MCL. The inventors also used MCL as a model for the therapeutic use of As2O3 in targeting cancers that over-expressed cyclin D1. Finally, the inventors also tested clinically the therapeutic use of As2O3 in patients with terminal or refractory MCL.

[0009] It is an object of this invention to provide agents and methods for degrading cyclin D1 in cancers. It is also an object of this invention to provide agents of As2O3 in the treatment of cancers related to cyclin D1 over-expression. Another object of this invention is to provide agents and the in vivo concentration of As2O3 needed to produce therapeutic effects in cancers over-expressing cyclin D1. This invention further provides methods, strategies, doses, and dosing schedule in the application of As2O3 in the clinical treatment of cancers over-expressing cyclin D1.

SUMMARY OF THE INVENTION

[0010] The inventors have discovered that As2O3 suppresses cyclin D1. The inventors also discovered that As2O3 initiated down-regulation of cyclin D1 by activating GSK-3β, which phosphorylates cyclin D1. The inventors also discovered that the IKKβ was activated, leading to phosphorylation of cyclin D1. The inventors further discovered that phosphorylated cyclin D1 was ubiquitinated. The inventors then showed that ubiquitinated cyclin D1 was degraded in the proteasome.

BRIEF DESCRIPTION OF DRAWINGS

[0011] These and other objects, features and advantages will become apparent upon reviewing the following detailed description of the preferred embodiments, in conjunction with the attached drawings, which are briefly described below.

[0012] FIG. 1 shows As2O3 induced apoptosis in MCL cells. A. MTI test of Jeko-1 and Granita-519 cells treated for 72 hours with As2O3. There was a dose and time dependent suppression of cellular proliferation. Viability significantly
decreased at or above 1 μM As2O3 as compared with baseline (one-way ANOVA with Dunnett’s post-tests, p<0.05) (triplicate experiments). B. Significant increase in apoptotic cells after As2O3 treatment. #: apoptotic cells that were annexin V positive and propidium iodide negative. C. Activation of caspase 3 by As2O3 treatment. Cleaved caspase 3 were detectable four hours after As2O3 treatment.

[0013] FIG. 2 shows down-regulation of cyclin D1 by As2O3 treatment. A. As2O3 (4 μM) induced a time dependent down-regulation of cyclin D1 in Jeko-1 and Granta-519 cells. Triplicate experiments and a representative Western blot demonstrated significant decrease in cyclin D1 level after 2 hours (one-way ANOVA with Dunnett’s post-tests, p<0.05). B. As2O3 (treatment for 8 hours) induced a dose dependent down-regulation of cyclin D1 in Jeko-1 and Granta-519 cells. Triplicate experiments and a representative Western blot demonstrated significant decrease in cyclin D1 level at or above 2 μM (one-way ANOVA with Dunnett’s post-tests, p<0.05). C. Semi-quantitative polymerase chain reaction showing that cyclin D1 gene transcription was unaffected by As2O3 treatment.

[0014] FIG. 3 shows dephosphorylation of retinoblastoma (RB) by As2O3 treatment in MCL lines. As2O3 treatment resulted in dephosphorylation of RB (significant decrease of phospho-Rb Ser-795 at or more than 8 hours of As2O3 treatment, triplicate experiments, one-way ANOVA with Dunnett’s post-tests, p<0.05). A representative Western blot was shown.

[0015] FIG. 4 shows As2O3 treatment induced phosphorylation of cyclin D1 and GS3-3A. A. Cell lysates immunoblotted with anti-phospho-cyclin D1 (Thr286). As2O3 treatment led to significantly increased phosphor-cyclin D1 (triplicate experiments, one-way ANOVA with Dunnett’s post-tests, p<0.05). B. Cell lysates immunoblotted with anti-phospho-cyclin GS3-3 (Thr216). As2O3 treatment led to greatly increased phosphoryl-GS3-3 (triplicate experiments, one-way ANOVA with Dunnett’s post-tests, p<0.05). C. Pre-incubation with 6-bromocuridine-3’-oxime (BIO; 10 μM) before As2O3 treatment (4 μM, 8 hour, 37°C) prevented cyclin D1 down-regulation, showing that GS3-3 was involved. Result a significant reduction of cyclin D1 as compared with control (triplicate experiments, one-way ANOVA with Dunnett’s post-tests, p<0.05).

[0016] FIG. 5 shows that IKK was involved in As2O3-induced down-regulation of cyclin D1. A. As2O3 treatment (4 μM for 2 hours) led to a significant increase in phospho-IKKαβ (Ser176/180) (triplicate experiments, one-way ANOVA with Dunnett’s post-tests, p<0.05). B. Pre-incubation with the IKK inhibitor BMS (10 mM, 30 minutes) successfully prevented As2O3-induced cyclin D1 down-regulation (triplicate experiments, one-way ANOVA with Dunnett’s post-tests, p<0.05). C. Cells were treated with As2O3 (4 μM, 2 hours), followed by lysis and immunoprecipitation with an anti-IKKαβ or anti-cyclin D1 antibody. The immunoprecipitates and the crude lysates were immunoblotted with anti-cyclin D1 and anti-IKKαβ antisera. As2O3 induced an increase in binding between IKKαβ and cyclin D1.

[0017] FIG. 6 is an As2O3 induced ubiquitination of cyclin D1 in MCL. A. Cell lysates were immunoprecipitation with anti ubiquitin (Ub) or anti-cyclin D1 antibody. The immunoprecipitates and the crude lysates were immunoblotted with anti-cyclin D1 and anti-ubiquitin antisera. As2O3 induced a significant increase in binding between cyclin D1 and ubiquitin (increase in ubiquitination from 30 minutes to 2 hours after As2O3 treatment as compared to the baseline, triplicate experiments, one-way ANOVA with Dunnett’s post-tests, p<0.05). A representative Western blot was shown.

[0018] FIG. 7 shows As2O3-induced cyclin D1 degradation involved the proteasome but not the lysosome in MCL. A. Pre-incubation with the proteasome inhibitors MG132 (MG, 30 μM), bortezomib (bort, 10 μg/ml) and lactacystin (lact, 10 μM) successfully prevented As2O3 induced cyclin D1 degradation. B. Pre-incubation with the lysosomal inhibitor ammonium chloride (NH4Cl, 2.5 mM) was ineffective in preventing As2O3-induced cyclin D1 degradation.

[0019] FIG. 8 is a schematic diagram showing the proposal degradation of cyclin D1 mediated by As2O3.

[0020] FIG. 9 is a response of mantle cell lymphoma to oral arsenic trioxide (As2O3). A. Case 6, with bilateral orbital infiltration at relapse (A1) that completely resolved (A2) after 4 months of oral-As2O3 treatment and ascobic acids, AA. B. Case 8, relapsing as leukemic phase and massive splenomegaly (B1), who achieved a partial remission after 8 months of treatment with oral-As2O3 and AA (B2). C. Case 8, with dense marrow infiltration (C1) that resolved (C2) after 8 months of treatment with oral-As2O3 and AA.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] Reference will now be made in detail to the presently preferred embodiments of the invention, which, together with the examples following the detailed description, serve to explain the principles of the invention.

[0022] The inventors discovered that As2O3 induced apoptosis in MCL lines at 2-4 μM, which was within the plasma levels achieved after As2O3 therapy. As2O3 induced a dose and time dependent suppression of cyclin D1. The suppression of cyclin D1 restored RB to a hypophosphorylated state, in parallel with a change in cell cycle. These biologic changes were consistent with the apoptosis observed upon As2O3 treatment.

[0023] The inventors further showed that the down-regulation of cyclin D1 mediated by As2O3 occurred at a post-transcriptional level. This might be expected, as cyclin D1 is under the transcriptional control of the immunoglobulin heavy chain gene enhancer in MCL, which is unlikely to be affected by As2O3. Furthermore, in physiologic conditions, the control of cyclin D1 during the cell cycle is also mediated in part via alteration in the stability of cyclin D1. This process is controlled by phosphorylation of cyclin D1 at Thr286, a process mediated by GS3-3.8,11 GS3-3 is itself tightly regulated. Mitogens inactivate GS3-3 by a pathway involving Ras, phosphatidylinositol 3 kinase (PI3K), and protein kinase Akt.23,24 Ras activates PI3K, which in turn activates Akt. Akt inactivates GS3-3 by phosphorylating it at serine residues.4 This removes the inhibition of GS3-3 on cyclin D1, allowing cyclin D1 to accumulate and thus activate cell cycling.

[0024] On the other hand, GS3-3 can also be activated by phosphorylation at a tyrosine residue 216 (Try216) in the kinase domain.24 Little is known, though, of the physiologic mechanisms controlling GS3-3 phosphorylation at Tyr-216. There is some evidence that GS3-3 might activate phosphorylate.25 In D. discoideum, the tyrosine kinase ZAKI phosphorylates GS3-3 in response to cAMP.25 In man-
malian cells, the tyrosine kinases Fyn,31 Crk32 and Pyk233,34 have been implicated in GSK-3β phosphorylation at Tyr-216. Therefore, an important novel observation in this study is the As₂O₃-mediated increase of GSK-3β Tyr-216 phosphorylation. How an inorganic molecule As₂O₃ might enhance GSK-3β phosphorylation remains to be defined. However, it has been shown that increases in calcium may lead to enhanced GSK-3β phosphorylation, via activation of the calcium sensitive kinase Pyk2.35 Whether As₂O₃ acts through a similar mechanism will have to be investigated. Nevertheless, the end result of As₂O₃-mediated increase in GSK-3β Tyr-216 phosphorylation is the increase in cyclin D1 Thr-286 phosphorylation, a key step in its degradation.

Another recently defined mechanism of regulating cyclin D1 is the IKK system. The IKK complex is the major regulatory component in the NF-kB pathway. It comprises the catalytic subunits IKKα and IKKβ, and a regulatory subunit IKKε/NEMO.36 Interestingly, IKKα has been shown recently to phosphorylate cyclin D1 at Thr-286, the same site targeted by GSK-3β. IKKα needs to be activated by phosphorylation at a serine residue 176 (Ser-176) before participating in the regulation of NF-kB by phosphorylating IkB.37,38 IKKα Ser-176 phosphorylation is mediated by NK-kB3 inducing kinase (NIK).39 Hence, the finding of As₂O₃-induced increase in IKK phosphorylation is another important original observation. Furthermore, As₂O₃-mediated an increase in physical interaction between IKK and cyclin D1, as shown in immunoprecipitation experiments. Finally, an IKK-specific inhibitor BMS-34554140 alleviated As₂O₃-induced cyclin D1 down-regulation. Taken together, these results indicated that IKK was also an effector of As₂O₃ treatment. The mechanism by which As₂O₃ increases IKK phosphorylation is unclear. However, NIK is activated by a host of stimuli, including tumor necrosis factor and interleukin-1. The potential interaction of As₂O₃ with these signaling molecules requires further studies.

The inventors further showed that As₂O₃-mediated cyclin D1 Thr-286 phosphorylation increased its ubiquitination. Moreover, the time course of ubiquitination was concordant with the timing of the biologic functions of As₂O₃ on the MCL lines. After As₂O₃ treatment, increased ubiquitination was first detected at 30 minutes and continued to increase. At two hours, significant down-regulation of cyclin D1 was first observed, which was associated with a parallel hypophosphorylation of RB. Finally, significant activation of caspase 3 was observed at four hours. These sequence of events were consistent with cyclin D1 down-regulation initiated by Thr-286 phosphorylation.

Cyclin D1 is a cytosolic and nuclear protein. Therefore, polyubiquitination is involved, which targets the protein to degradation in proteasomes. Indeed, we showed that inhibition of proteasomes successfully prevented As₂O₃-induced down-regulation of cyclin D1. On the other hand, inhibition of lysosomes, the site of degradation of monoubiquitinated proteins,39 did not interfere with As₂O₃-induced down-regulation of cyclin D1. These results confirm that As₂O₃ down-regulated cyclin D1 by promoting its proteasomal degradation.

The capability of As₂O₃ in augmenting proteasomal degradation of cyclin D1 is reminiscent of its action on another fusion oncoprotein PML-RARA in APL. As₂O₃ enhances the conjugation of a ubiquitin-related peptide SUMO-1 to the PML part of the PML-RARA protein.41 This directs PML-RARA to nuclear bodies, which are nuclear matrix domains containing 11S proteosome constituents recruited by As₂O₃ treatment. In this way, As₂O₃ triggers proteosome-dependent degradation of SUMO-conjugated PML-RARA. Therefore, As₂O₃ may act together with component of the proteasomal system to effect degradation of target proteins. Findings of the current study corroborate with this proposition.

The inventors have clearly shown that As₂O₃ suppresses MCL cell growth by targeting cyclin D1. Furthermore, there are a number of important ramiﬁcations arising from this study that will form the lead for further investigations. As₂O₃ appears to be capable of inducing the phosphorylation of not only GSK-3β, but also IKK. The issues of whether this is mediated by different mechanisms or a common pathway, and the possibility that As₂O₃ might mediate phosphorylation of other biologically important molecules, will warrant exploration. Finally, cyclin D1 overexpression is pathogenetically important in a vast diversity of cancers. It is important to determine if As₂O₃ also targets cyclin D1 in these cancers, and is therefore of therapeutic potential.

Based on these observations, the inventors used oral-As₂O₃ in the treatment of 14 patients with refractory or relapsed MCL, which over-expressed cyclin D1. The inventors observed an overall response in 9 patients (64%). Four patients achieved complete remission, two patients complete remission unconfirmed, and three patients with partial remissions. These results were very good, given that these patients had refractory or relapsed disease. These clinical observations obtained by the inventors are a direct in vivo proof of the inventors’ observations in their experimental system.

Taken together, the inventors have discovered several novel findings. The inventors have discovered that As₂O₃ decreased cyclin D1. The inventors further discovered that the decrease in cyclin D1 was post-transcriptional. The inventors moreover discovered that As₂O₃ induced GSK-3β and IKK activation and hence phosphorylation of cyclin D1. The inventors then showed that phosphorylated cyclin D1 was degraded in the proteasome. Finally, the inventors have made the novel observation that oral-As₂O₃ induced a high response rate clinically in patients with refractory or relapsed MCL, a cancer that over-expressed cyclin D1.

The present invention of using oral arsenic trioxide in suppressing cyclin D1 is an important paradigm applicable to the treatment of cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation.

The following delivery systems, which employ a number of routinely used pharmaceutical carriers, are only representative of the many embodiments envisioned for administering the instant compositions.

Injectable drug delivery systems include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g., ethanol, propylene glycol and sucrose) and polymers (e.g., polycaprolactone and PLGA’s). Implantable systems include rods and discs, and can contain excipients such as PLGA and polycaprolactone.

Oral delivery systems include tablets and capsules. These can contain excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrrolidone, other cellulose materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulose materi-
als), disintegrating agents (e.g., starch polymers and cellulose materials) and lubricating agents (e.g., stearates and tale).

Transmucosal delivery systems include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g., propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylcellulose and hydroxypropylmethylcellulose).

Dermal delivery systems include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, penetration enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyzylypolidone). In one embodiment, the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer.

Solutions, suspensions and powders for reconstructible delivery systems include vehicles such as suspending agents (e.g., gums, xanthans, celluloses and sugars), humectants (e.g., sorbitol), solubilizers (e.g., ethanol, water, PEG and propylene glycol), surfactants (e.g., sodium lauryl sulfate, Span 20, and cetyl pyridine), preservatives and antioxidants (e.g., parabens, vitamins E and C, and ascorbic acid), anti-caking agents, coating agents, and chelating agents (e.g., EDTA).

EXAMPLE 1 OF A_s_3O_3 IN MCL BY TARGETING CYCLIN D1

Call lines. The MCL lines Jeko-1 and Granta-519 were obtained from German Collection of Microorganisms and Cell Cultures (ACC 553 and ACC 342, Braunschweig, Germany). Jeko-1 cells were cultured in RPMI 1640 with 20% fetal bovine serum (FBS), and Granta-519 cells in DMEM with 10% FBS, both with 50 μg/ml penicillin and 50 μg/ml streptomycin, at 5% CO₂.

EXAMPLE 2 OF A_s_3O_3 IN MCL BY TARGETING CYCLIN D1

Reagents and Antibodies. Reagents and antibodies used included cell culture reagents (Invitrogen, Carlsbad, Calif., USA); kinase inhibitors and their inactive analogues (Calbiochem, Darmstadt, Germany); anti-c-Myc (clone Tyr216, Try216) (Upstate, Lake Placid, N.Y., USA); anti-cyclin D1 (phospho-cyclin D1 (Thr-286), GSK3β, phospho-GSK3β (Tyr-216), IκB kinase (IκK) α/β, phospho-IKKβ/ε (serine 176/180, Ser-176/180), RB and phospho-RB (serine 795, Ser-795), caspase-3 and β-actin (Cell Signaling Technology, Beverly, Mass., USA); protein G-agarose (Upstate); ECL kit (Amersham, Piscataway, N.J., USA); cell proliferation kit I (MTT) (Roche Applied Science, Indianapolis, Ind., USA); annexin V-FITC Kit (Beckman Coulter, Fullerton, Calif., USA); and RNasy Kit and One-Step RT-PCR Kit (Qiagen, Valencia, Calif., USA).

EXAMPLE 3 OF A_s_3O_3 IN MCL BY TARGETING CYCLIN D1

Cell viability assays. Cells were seeded on 96-well microplates at 2x10^4/well in 100 μl growth medium containing different concentration of A₃S₃O₃ as indicated at 37°C for 72 hours. MTT labeling reagent (10 μl, 5 mg/ml) (Roche Applied Science, Indianapolis, Ind., USA) was added to each well at 37°C for 4 hours, followed by 100 μl solubilization at 37°C overnight. Solubilized formazan crystals were quantified spectrophotometrically at 590 nm with a microplate ELISA reader.

EXAMPLE 4 OF A_s_3O_3 IN MCL BY TARGETING CYCLIN D1

Apoptosis assay. Cells were seeded at 1x10⁴/ml in different concentrations of A₃S₃O₃, as indicated at 37°C for 24 hours, harvested, rinsed in ice-cold phosphate buffered saline (PBS), and resuspended in 500 μl binding buffer containing annexin V-FITC and propidium iodide (PI) (Beckman Coulter, Fullerton, Calif., USA) for 20 minutes on ice. The percentages of apoptotic cells (annexin-V positive, PI negative) were determined on a flow cytometer (Epics, Beckman Coulter) with appropriate color compensation.

EXAMPLE 5 OF A_s_3O_3 IN MCL BY TARGETING CYCLIN D1

Semiquantitative reverse transcription polymerase chain reaction (RT-PCR) for cyclin D1. Cells were seeded at a density of 1x10⁴/ml in different concentrations of A₃S₃O₃ at 37°C for 8 hours, washed with PBS buffer and lysed with RTL buffer. RNA was extracted with an RNasey Kit, followed by cDNA synthesis and a 30-cycle PCR with a One-Step RT-PCR Kit with the forward primer 5’-CTG GCT AGT AAC TAC CTG GA-3’ and the reverse primer 5’-GTC ACA GAT GAC TCT TG-3’. Cycling conditions were denaturation (1 minute at 94°C, first cycle 5 minutes), annealing (2 minutes at 50°C) and extension (3 minutes at 72°C, last cycle 10 minutes).

EXAMPLE 6 OF A_s_3O_3 IN MCL BY TARGETING CYCLIN D1

Western Blotting Analysis. Cells were seeded at a density of 1x10⁴/ml overnight. Where applicable, cells were pre-treated with various inhibitors for 30 minutes, and then incubated with 4 μM A₃S₃O₃ for different time periods as indicated. Cells were lysed in lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 5 mM EDTA, 40 mM NaPO₄, pH 7.5, 1% Triton X-100, 4 μg/ml aprotinin, 1 mM dithiothreitol, 200 μM Na₂VO₃ 0.7 μg/ml pepstatin, 100 μM phenylmethylsulfonyl fluoride, and 2 μg/ml leupeptin). Clarified lysates were resolved on 12% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked with 5% non-fat milk, washed, incubated with the appropriate antibodies followed by horseradish peroxidase-conjugated secondary antisera. Immunoreactive bands were visualized with chemiluminescence with the ECL kit, detected on X-ray films and quantified by densitometric scanning (Eagle Eye II still video system, Stratagene, La Jolla, Calif., USA).

EXAMPLE 7 OF A_s_3O_3 IN MCL BY TARGETING CYCLIN D1

Coimmunoprecipitation Assays. Cells were seeded at 1x10⁴/ml overnight treated with 4 μM A₃S₃O₃ at 37°C for different time periods as indicated, and lysed in lysis buffer. Cell lysates were incubated with an anti-cyclin D1, anti-ubiquitin, anti-calpain 2 or anti-IKKe/β antibodies (4
RESULTS OF EXAMPLE 1-7 OF \textit{As}_{2}O_{3} \textit{IN MCL BY TARGETING CYCLIN D1}

\textbf{[0047]} \textit{As}_{2}O_{3} \textit{induced dose and time dependent apoptosis in MCL cells. MTT test showed that \textit{As}_{2}O_{3} \textit{induced a dose-dependent cytotoxicity in Jeko-1 and Granata-519 cells (FIG. 1A). Flow cytometric analysis showed that \textit{As}_{2}O_{3} \textit{treatment led to induction of apoptosis (FIG. 1B). Western blot analysis showed that caspase 3 activation was involved in \textit{As}_{2}O_{3} \textit{-induced apoptosis (FIG. 1C).}}}

\textbf{[0048]} \textit{Cyclin D1 was down-regulated in MCL by \textit{As}_{2}O_{3}. To determine the molecular mechanisms of \textit{As}_{2}O_{3} \textit{-induced apoptosis in MCL, the expression of cyclin D1 was examined. Western blot analysis showed that \textit{As}_{2}O_{3} \textit{induced a time and dose dependent suppression of cyclin D1 in both cell lines. Treatment with \textit{As}_{2}O_{3} \textit{at 4 \mu M led to suppression of cyclin D1, first detectable at 2 hours and almost complete at 8-12 hours (FIG. 2A). \textit{As}_{2}O_{3} \textit{suppression of cyclin D1 was also dose-dependent (FIG. 2B).}}}

\textbf{[0049]} \textit{As}_{2}O_{3} \textit{induced down-regulation of cyclin D1 disrupted its signaling. To investigate if cyclin D1 down-regulation is biologically relevant, RB phosphorylation was investigated. \textit{As}_{2}O_{3} \textit{treatment led to a time dependent decrease in RB phosphorylation, which occurred at a similar time-frame as compared with cyclin D1 down-regulation (FIGS. 3A and B). Cell cycle analysis by flow cytometry showed that there was an increase in the proportion of apoptotic cells.}

\textbf{[0050]} \textit{Down-regulation of cyclin D1 by \textit{As}_{2}O_{3} \textit{was post-transcriptional RT-PCR showed that cyclin-D1 gene transcription was unaffected by \textit{As}_{2}O_{3} \textit{treatment of up to 8 \mu M, suggesting that the down-regulation of cyclin D1 was post-transcriptional (FIG. 4A).}}

\textbf{[0051]} \textit{As}_{2}O_{3} \textit{-induced cyclin D1 down-regulation was related to \textit{GSK3\beta} activation. Western blot analysis showed that \textit{As}_{2}O_{3} \textit{treatment resulted in significant increases in cyclin D1 phosphorylation at Thr-286, a prerequisite for cyclin D1 degradation (FIG. 4B). Cyclin D1 phosphorylation by \textit{GSK3\beta} requires prior activation of \textit{GSK3\beta} by phosphorylation at Tyr-216. \textit{As}_{2}O_{3} \textit{treatment in fact significantly increased \textit{GSK3\beta}-Tyr-216 phosphorylation, suggesting that \textit{GSK3\beta} might mediate \textit{As}_{2}O_{3} \textit{-induced cyclin D1 phosphorylation and hence degradation. To confirm the role of \textit{GSK3\beta} as a mediator of \textit{As}_{2}O_{3}, Jeko-1 cells were pre-incubated with the \textit{GSK3\beta} inhibitor 6-bromodindirubin-3'-oxime (BIO; 10 \mu M) before \textit{As}_{2}O_{3} \textit{treatment. The results showed that BIO successfully prevented \textit{As}_{2}O_{3} \textit{-induced down-regulation of cyclin D1. Collectively, these observations indicated that \textit{As}_{2}O_{3} \textit{down-regulated cyclin D1 post-transcriptionally, probably by increasing its degradation.}}}

\textbf{[0052]} \textit{As}_{2}O_{3} \textit{-induced cyclin D1 down-regulation was also dependent on \textit{IKK\alpha/\beta}. To determine if \textit{IKK} was involved in \textit{As}_{2}O_{3} \textit{-induced down-regulation of cyclin D1, \textit{IKK\alpha/\beta} phosphorylation at Ser-178/180 was examined. \textit{As}_{2}O_{3} \textit{significantly increased \textit{IKK\alpha/\beta} Ser-178/180 phosphorylation, which was required for activation of \textit{IKK\alpha/\beta} (FIG. 5A). Pre-treatment with the \textit{IKK\alpha/\beta} inhibitor BMS-345541 (BMS; 10 \mu M) significantly prevented \textit{As}_{2}O_{3} \textit{-induced cyclin D1 down-regulation, suggesting that \textit{IKK\alpha/\beta} was a molecular mediator of \textit{As}_{2}O_{3} (FIG. 5B). Immunoprecipitation with an anti-\textit{IKK\alpha/\beta} antibody showed that cyclin D1 bound \textit{IKK\alpha/\beta}. Similarly, when cyclin D1 was immunoprecipitated, \textit{IKK\alpha/\beta} was also confirmed to co-immunoprecipitate (FIG. 5C). These results confirmed that \textit{As}_{2}O_{3} \textit{activated \textit{IKK\alpha/\beta}, which participated in the down-regulation of cyclin D1.}}

\textbf{[0053]} \textit{As}_{2}O_{3} \textit{promoted cyclin D1 ubiquitination. To study if \textit{As}_{2}O_{3} \textit{-induced cyclin D1 down-regulation was mediated via ubiquitination, immunoprecipitation experiments were performed on lysates from Jeko-1 cells treated with \textit{As}_{2}O_{3}. Immunoprecipitation with an anti-ubiquitin antibody showed a time-dependent increase in bound cyclin D1 (FIGS. 6A and B). Similarly, lysates immunoprecipitated with an anti-cyclin D1 antibody also showed a time-dependent increase in bound ubiquitin. These results showed that \textit{As}_{2}O_{3} \textit{promoted cyclin D1 ubiquitination, confirming that \textit{As}_{2}O_{3} \textit{-induced \textit{GSK3\beta} and \textit{IKK\alpha/\beta} activation was biologically relevant.}}

\textbf{[0054]} \textit{As}_{2}O_{3} \textit{induced cyclin D1 degradation in 26S and 20S proteasomes but not lysosomes. Pre-incubation of Jeko-1 cells with the 26S and 20S proteasome inhibitors MG132 (30 \mu M), bortezomib (10 \mu M) and lactacystin (10 \mu M) attenuated \textit{As}_{2}O_{3} \textit{-induced cyclin D1 down-regulation (FIG. 7A). However, pre-incubation with the lysosomal inhibitor ammonium chloride (NH\textsubscript{4}Cl) had no effect on \textit{As}_{2}O_{3} \textit{-induced down-regulation of cyclin D1 (FIG. 7B). The results confirmed that \textit{As}_{2}O_{3} \textit{down-regulated cyclin D1 by promoting its ubiquitination, hence targeting it to the proteasome for degradation.}}

\textbf{[0055]} \textit{Overall model An overall model of the action of \textit{As}_{2}O_{3} \textit{on MCL is shown in FIG. 8.}}

\textbf{EXAMPLE 8 OF ORAL-\textit{As}_{2}O_{3} \textit{IN THE CLINICAL TREATMENT OF PATIENTS WITH REFRACTORY AND RELAPSED MCL THAT OVER-EXPRESSION CYCLIN D1}}

\textbf{[0056]} \textit{Patients, Consenting patients with relapsed or refractory B-cell lymphomas, and an ECOG performance status of <2 were recruited All patients gave informed consent, and the treatment was approved by the institute review board of Queen Mary Hospital.}

\textbf{Example 9 OF ORAL-\textit{As}_{2}O_{3} \textit{IN THE CLINICAL TREATMENT OF PATIENTS REFRACTORY AND RELAPSED MCL THAT OVER-EXPRESSION CYCLIN D1}}

\textbf{[0057]} \textit{Treatment. Treatment was initiated with oral-\textit{As}_{2}O_{3} (10 mg/day for patients below 70 years old with normal renal function; 5 mg/day for patients over 70 years old, or with impaired renal function), ascorbic acid (AA. 1 g/day) and chlorambucil (4 mg/day) as outpatients until disease response or progression was documented. In patients with bulky disease, debulking with VIP (vincristine 2 mg/day×1, prednisolone 30 mg/day×14 and procarbazine 50-100 mg/day×14) was used. After maximum response was achieved, chlorambucil was taken off and a maintenance regimen of \textit{As}_{2}O_{3} (5-10 mg/day) and AA (1 g/day) was given for two weeks every 2 months for a planned two years. Responses were classified according to standard NCI criteria, and monitored by regular physical examination, marrow and blood assessment, and computerized tomographic scans.}

\textbf{RESULTS OF EXAMPLES 8-9 OF ORAL-\textit{As}_{2}O_{3} \textit{IN THE CLINICAL TREATMENT OF PATIENTS WITH REFRACTORY AND RELAPSED MCL THAT OVER-EXPRESSION CYCLIN D1}}

\textbf{[0058]} \textit{Characteristics of patients with MCL. Table 1 shows results of the clinical use of oral-\textit{As}_{2}O_{3} in patients
with refractory or relapsed mantle cell lymphoma that over-expressed cyclin D1. The results showed an overall response rate of 64%. Four patients achieved complete remission (CR), whereas two patients achieved complete remission unconfirmed. Of the fourteen patients treated (Table 1), eleven had advanced relapses (R) (R2, n=5; R3, n=4; R4, n=2). Three patients treated in R1 had advanced age (76, 77 and 90 years). All but two patients had received an anthracycline based multi-agent chemotherapy. Other previous treatment included rituximab (n=8), autologous hematopoietic stem cell transplantation (HSCT) (n=3), and bortezomib (n=1). Other poor prognostic indicators included marrow infiltration (n=11) and extensive extranodal involvement (n=9), so that 12/14 (86%) cases had stage IV disease. The median time from initial diagnosis to As₂O₃ treatment was 33 (8-85) months.

**[0059]** Treatment response. Nine patients responded, giving an OR rate of 64%. Four patients (cases 1-4) achieved CR. Two patients (cases 5, 6) achieved unconfirmed CR (CRu). They had become asymptomatic without any detectable superficial diseases (FIG. 9A). Marrow and peripheral blood involvement was also cleared. However, small residual internal lymph nodes remained. These lymph nodes were negative on gallium scan and had remained static in size. Three patients had partial responses (PR) with >50% reduction in the size of assessable lymph nodes (FIGS. 9B and C).

**[0060]** Outcome. Of the four patients with CR, one had relapsed at 16 months. She achieved a CR3 again with daily As₂O₃ and resumption of chlorambucil. Two patients were still on maintenance As₂O₃+AA treatment, while one had

---

**TABLE 1**

Clinical-pathologic features and treatment outcome of 14 patients with relapsed or refractory MCL.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Sites</th>
<th>Previous Treatment</th>
<th>Time*</th>
<th>No Sites</th>
<th>Total As₂O₃</th>
<th>CR</th>
<th>CRu</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 M/69 II</td>
<td>Colon, abdomen</td>
<td>FND × 6, COPP × 6</td>
<td>56 m</td>
<td>2</td>
<td>Cervical</td>
<td>140 mg</td>
<td>CR</td>
<td>Off Rx, 28 m+</td>
</tr>
<tr>
<td>2 M/63 IV</td>
<td>BM, generalized LN</td>
<td>R-CCEP × 6, BVP × 6</td>
<td>11 m</td>
<td>2</td>
<td>BM, cervical</td>
<td>160 mg</td>
<td>CR</td>
<td>On Rx, 13 m+</td>
</tr>
<tr>
<td>3 M/65 IV</td>
<td>BM, mesenteric, generalized LN</td>
<td>FND × 7, IMVP × 2, R-DHAP × 8</td>
<td>85 m</td>
<td>3</td>
<td>Eye</td>
<td>120 mg</td>
<td>CR</td>
<td>On Rx, 17 m+</td>
</tr>
<tr>
<td>4 F/77 IV</td>
<td>Pleura, generalized LN</td>
<td>Cib</td>
<td>33 m</td>
<td>1</td>
<td>Groin, jaw</td>
<td>140 mg</td>
<td>CR</td>
<td>R2 at 16 m, CR again with As₂O₃ + Cib</td>
</tr>
<tr>
<td>5 M/70 III</td>
<td>Generalized LN</td>
<td>COPP × 2, IMVP × 6, Cib</td>
<td>85 m</td>
<td>4</td>
<td>Cervical, abdomen</td>
<td>250 mg</td>
<td>CRu</td>
<td>R5 at 20 m, on As₂O₃ + Cib</td>
</tr>
<tr>
<td>6 M/76 IV</td>
<td>BM, generalized LN</td>
<td>CEOP × 7</td>
<td>19 m</td>
<td>1</td>
<td>BM, leukemic, eyes, generalized LN</td>
<td>210 mg*</td>
<td>CRu</td>
<td>On Rx, 8 m+</td>
</tr>
<tr>
<td>7 M/58 IV</td>
<td>BM, generalized LN</td>
<td>CEOP × 6, R-ESHAP × 6</td>
<td>18 m</td>
<td>2</td>
<td>Generalized skin</td>
<td>140 mg</td>
<td>PR</td>
<td>On Rx, 3 m+</td>
</tr>
<tr>
<td>8 M/51 IV</td>
<td>BM, leukemic, liver, spleen</td>
<td>CHOP × 6, CibaPP × 2</td>
<td>18 m</td>
<td>2</td>
<td>BM, LN, liver, spleen, leukemic</td>
<td>300 mg*</td>
<td>PR</td>
<td>Died at 16 m</td>
</tr>
<tr>
<td>9 M/51 IV</td>
<td>Generalized LN, spleen, BM, scalp, eye</td>
<td>CVAD × 7, CEOP × 2, R-DHAP × 3, Thal</td>
<td>25 m</td>
<td>4</td>
<td>BM, LN, scalp</td>
<td>NA*</td>
<td>Static</td>
<td>On Rx, 8 m+</td>
</tr>
<tr>
<td>10 F/76 IV</td>
<td>General LN, BM, scalp</td>
<td>R-COPP × 6</td>
<td>12 m</td>
<td>2</td>
<td>BM, LN</td>
<td>160 mg*</td>
<td>PR</td>
<td>Died at 6 m</td>
</tr>
<tr>
<td>11 M/90 IV</td>
<td>BM, leukemic</td>
<td>Cib</td>
<td>8 m</td>
<td>1</td>
<td>BM, leukemic</td>
<td>NA</td>
<td>NR</td>
<td>Died at 4 m</td>
</tr>
<tr>
<td>12 M/54 IV</td>
<td>BM, gut, liver, spleen, leukemic</td>
<td>Cib</td>
<td>36 m</td>
<td>3</td>
<td>BM, generalized LN, spleen</td>
<td>NA</td>
<td>Static</td>
<td>Died at 17 m</td>
</tr>
<tr>
<td>13 F/57 IV</td>
<td>Generalized LN, BM, spleen</td>
<td>CEP × 6, DHAP × 6, NOPP × 5, Cib</td>
<td>36 m</td>
<td>3</td>
<td>BM, LN</td>
<td>NA</td>
<td>NR</td>
<td>Died at 1 m</td>
</tr>
<tr>
<td>14 M/63 IV</td>
<td>Generalized LN, pleura, BM</td>
<td>CEP × 6, AHSC, R-DHAP × 6, Thal, vechide, FND</td>
<td>72 m</td>
<td>3</td>
<td>BM, generalized LN</td>
<td>NA</td>
<td>NR</td>
<td>Died at 1 m</td>
</tr>
</tbody>
</table>

M: male; F: female; LN: lymphadenopathy; BM: bone marrow; m: months; R: rituximab; COPP: cyclophosphamide, epirubicin, vincristine, prednisolone; FND: fludarabine, mitoxantrone, dexrazoxane; DHAP: cisplatinum, cytosine arabinoside, dexmethasone; Thal: thalidomide; Cb: chlorambucil; NA: not available; CR: complete remission; CRu: complete remission (unconfirmed); PR: partial remission; NR: no response.
completed the planned two years of treatment. Of the two patients with CR2, one patient had relapsed at 20 months. He achieved CR5 again with As2O3 and chlorambucil therapy. For the three patients with PR, one patient developed progressive disease while on maintenance therapy 12 months later and died of refractory lymphoma. Two defaulted treatment and both relapsed.

[0061] Toxicity. Significant (W.H.O grade 3-4) neutropenia and thrombocytopenia was observed in 7 patients. These patients had previously multiple chemotherapy, or autologous HSCT. The neutropenia responded to hematopoietic growth factors. No significant sepsis or bleeding were observed. Other side effects included fever (n=7), herpes zoster reactivation (n=3), fluid accumulation (n=2), nausea (n=3) and headache (n=2). No significant QT prolongation or arrhythmia was observed. Five patients did not report any side effects at all.

REFERENCES


What is claimed is:

1. A method for inhibiting cyclin D1 production in a cell, comprising contacting the cell with an amount of arsenic trioxide effective to inhibit cyclin D1 production therein.

2. A method according to claim 1, wherein the cell is a cancer cell.

3. A method according to claim 2, wherein the cell is a human mantle cell lymphoma cell.

4. A method according to claim 2, wherein the cancer cell resides within a patient and the arsenic trioxide is administered orally.

5. A method according to claim 4, wherein the cancer cell is a human female genital tract cancer, a digestive tract cancer, or a malignant lymphoma.

6. A method for inhibiting growth of mantle cell lymphoma (MCL) in a subject afflicted thereby, comprising administering to the subject an MCL growth inhibiting amount of arsenic trioxide in a pharmaceutically acceptable vehicle.

7. A method according to claim 2, wherein the arsenic trioxide is administered orally.

8. A method according to claim 2, wherein MCL growth is inhibited by preventing overexpression of cyclin D1.

9. A method according to claim 3, wherein MCL growth is inhibited by preventing overexpression of cyclin D1.